ClinicalTrials.gg

Program

IDP-121

A development code. Also written as “IDP-121 Lotion” and “IDP 121 Lotion”.

Its studies are mostly in Acne Vulgaris · Small Cell Lung Carcinoma · Multiple Myeloma, led by 2 companies.

Furthest: phase 3, since Jul 2, 20157 company-led studies, 2 open or runningNext primary completion: Jul 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companies50 open or runningphase 3since Jul 2, 2015Jul 2, 2015none ahead
IDP Discovery Pharma S.L.22 open or runningphase 2since May 3, 2023May 3, 2023Jul 30, 2028phase 2 · NCT07864207

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 2, 2015First study: phase 3 study in Acne VulgarisNew to Bausch Health CompaniesBausch Health Companies · NCT02491060 · 800 enrolled
  2. Aug 26, 2015Phase 3 study in Acne VulgarisBausch Health Companies · NCT02535871 · 800 enrolled
  3. Jul 6, 2016Phase 1 study in Acne VulgarisBausch Health Companies · NCT02849860 · 20 enrolled · United States
  4. Oct 11, 20162 phase 3 studies in Acne VulgarisBausch Health Companies · NCT02965456, NCT02932306
  5. May 3, 2023IDP Discovery Pharma S.L.'s first study: phase 2 study in Multiple MyelomaNew to IDP Discovery Pharma S.L.IDP Discovery Pharma S.L. · NCT05908409 · 37 planned · Spain
  6. Sep 29, 2026Phase 2 study in Small Cell Lung CarcinomaIDP Discovery Pharma S.L. · NCT07864207 · 60 planned · Spain

Ahead

  1. Jul 30, 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaIDP Discovery Pharma S.L. · NCT07864207

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07864207Small Cell Lung Carcinoma · Spain2RecruitingIDP Discovery Pharma S.L.Jul 30, 202860
NCT05908409Multiple Myeloma · Spain2RecruitingIDP Discovery Pharma S.L.Dec 22, 202537
NCT02965456Acne Vulgaris · United States3CompletedBausch Health CompaniesFeb 23, 2017820
NCT02932306Acne Vulgaris · United States3CompletedBausch Health CompaniesFeb 22, 2017820
NCT02849860Acne Vulgaris · United States1CompletedBausch Health CompaniesSep 201620
NCT02535871Acne Vulgaris3UNKNOWNBausch Health CompaniesJul 2016800
NCT02491060Acne Vulgaris3UNKNOWNBausch Health CompaniesJul 2016800

How it is read

Names in the registry

  • “IDP-121 Lotion”, 4 entries
  • “IDP-121”, 2 entries
  • “IDP 121 Lotion”, 1 entry

Codes read as this program: IDP121.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.